Promotion of Research and Innovation in Pharma MedTech Sector Scheme

समाचार में क्यों

  • Government approved Rs 1,600 crore in financial assistance for 41 pharma and MedTech innovation projects under the first call of PRIP.

मुख्य शब्द

PRIP Scheme

Promotion of Research and Innovation in Pharma-MedTech Sector scheme aimed at promoting breakthrough drug discovery.

Biosimilars

Biological medical products highly similar to already approved reference biopharmaceuticals with no clinical differences.

Complex Generics

Generic drugs with complex active ingredients, formulations, or routes of delivery requiring advanced R&D.

CAR-T Therapy

Chimeric Antigen Receptor T-cell therapy, an immunotherapy altering T-cells genetically to target cancer cells.

What is the PRIP Scheme?

  • Launched by Department of Pharmaceuticals to shift Indian pharma from high-volume generic production to high-value innovation.
  • Provides financial grants to establish Centres of Excellence and support R&D in priority focus areas across industry and academia.
  • Encourages private sector R&D expenditure through public co-funding mechanisms.

Key focus areas and approved grants

  • Approved 41 projects expected to catalyze Rs 3,020 crore of private investment, bringing total R&D pipeline value to Rs 4,620 crore.
  • Covers 27 projects in New Chemical Entities/Medicines, 5 in Complex Generics and Biosimilars, and 9 in Novel Medical Devices.
  • Supports 19 MSME/startup projects alongside 22 large domestic pharmaceutical firm ventures.

Why it matters

  • Addresses critical vulnerabilities in biologicals, CAR-T cell therapies, advanced diagnostics, and antimicrobial resistance (AMR) novel drugs.
  • Strengthens domestic IP creation and export value addition beyond standard low-margin generic formulation manufacturing.

प्रीलिम्स तथ्य

  • PRIP target priority areas include New Chemical Entities, Biosimilars, and High-End Medical Devices.

मेंस चर्चा

  • Transition of Indian pharmaceutical industry from the world's pharmacy of generics to an innovation-led intellectual property hub.

स्रोत: PIB Press Release

समान विषय · पिछले पेपर

UPSC ने यह पहले भी पूछा है

ये पिछले वर्षों के प्रश्न उसी विषय पर हैं। अभ्यास के लिए खोलें।

  1. 2024 · Q145 · UPPGS

    “राष्ट्रीय बौद्धिक सम्पदा अधिकार नीति” के संदर्भ में निम्नलिखित कथनों पर विचार कीजिए: 1. यह दोहा विकास एजेंडा और TRIPS समझौते के प्रति भारत की प्रतिबद्धता को दोहराती है। 2. भारत में बौद्धिक सम्पदा अधिकारों के विनियमन के लिये औद्योगिक नीति एवं संवर्धन विभाग (DIPP) नोडल अभिकरण है। उपर्युक्त में से कौन-सा/से कथन सही है? नीचे दिए गए कूट से सही उत्तर चुनिए।

    उत्तर देखें →

← सभी प्रीलिम्स + मेंस नोट्स · 1 October 2026

PDF
Daily news · PIB · quiz — Free